Ipsen news | Ipsen Global

Stories

Discover all of the trending stories of Ipsen Group.

Explore more by category

Filter

Period

Filter by

recent search

Showing: 15 of 120 stories

Primary Biliary Cholangitis: The Power of Patient Reported Outcomes
 –  – 2 mins read

 – 2 mins read

Primary Biliary Cholangitis: The Power of Patient Reported Outcomes

“The important thing with PBC is to take a holistic view of it, and think ‘What are the problems we are trying to solve? The first is the risk of progression to cirrhosis, and the other is symptoms and quality…


Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
 –  – 1 mins read

 – 1 mins read

Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics

Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.


The Liver Meeting 2023: Innovating for people living with rare liver diseases
 –  – 1 mins read

 – 1 mins read

The Liver Meeting 2023: Innovating for people living with rare liver diseases

Jennifer Schranz (Ipsen’s Global Head of Rare Diseases) attended The Liver Meeting from November 10-14, sharing key insights from her time onsite and explaining why scientific congresses are vital in helping advance innovation for patients. 


Ipsen’s mission to accelerate innovation in oncology
 –  – 2 mins read

 – 2 mins read

Ipsen’s mission to accelerate innovation in oncology

The outputs from the European Society of Medical Oncology (ESMO) Congress this year encompassed several important new data announcements, highlighting key advances in the development of therapies for people living with cancer.  However, cancer remains a formidable global health challenge,…


Examining the European Pharma legislation: EFPIA publishes the Dolon Report
 –  – 1 mins read

 – 1 mins read

Examining the European Pharma legislation: EFPIA publishes the Dolon Report

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…